Fibromyalgia

EULAR/PReS Standards for Transitional Care of Juvenile-Onset Rheumatic Diseases

Panel advises that up to 50% of young patients with juvenile-onset rheumatic diseases fail to successfully transition to adult rheumatology services.

Clinician Roundtable: Effective Management of Noninfectious Uveitis

Autoimmune uveitis is usually a diagnosis of exclusion. Part of the challenge of effective management of noninfectious uveitis is that it is not really a ...

Video Review: Differentiating Septic and Reactive Arthritis

Seronegative spondyloarthropathies associated with human leukocyte antigen (HLA) B27 antigens can manifest as an acute inflamed joint and must be differentiated from septic arthritis.

Lead Investigator Discusses Phase 3 Trial of IL-17A Inhibitor in PsA

Philip Mease, MD, clinical professor, University of Washington School of Medicine, Seattle, discusses the treatment of psoriatic arthritis (PsA) by inhibiting interleukin (IL)-17A with the ...

When Should Rheumatologists Refer Patients for Evaluation by an Orthopedic Surgeon?

Michael M. Alexiades, MD, met with Rheumatology Advisor to discuss the timely referral of patients with inflammatory arthritides who may be candidates for operative intervention.

Evaluation of the Pediatric Patient With Joint Pain and Swelling

Watch a video providing a comprehensive review of the distinguishing factors between the presentation of septic arthritis and Lyme arthritis.

VIDEO: Discussing the Use of Biosimilars for Rheumatic Disease

Discussion of the recent introduction of biosimilar agents into the treatment armamentarium for rheumatic disease.

Delayed Recognition of Spondyloarthritis: Diagnostic Challenges & Opportunities

Delayed diagnosis is associated with worse outcomes and poor treatment responses in patients with spondyloarthritis. Andrew Vreede, MD, University of Wisconsin School of Medicine and ...

Looking Beyond Corticosteroids to Treat Noninfectious Uveitis

The recent US Food and Drug Administration (FDA) approval of adalimumab (Humira®, AbbVie) for the treatment of noninfectious intermediate, posterior, and pan-uveitis is the first ...

Looking Beyond Traditional CV Risk Factors to Predict CV Events in PsA

In addition to traditional cardiovascular risk factors, increased PsA disease activity also appears to increase cardiovascular risk.

Latest News

Psoriatic Arthritis Tumor Necrosis Factor Inhibitor Persistence in Patients with Psoriatic Arthritis

Tumor Necrosis Factor Inhibitor Persistence in Patients with Psoriatic Arthritis

TNFi persistence and factors influencing persistence were investigated in patients who were treated with TNFi therapy for the first time.

Psoriatic Arthritis Tofacitinib or Adalimumab vs Placebo for Patients With Psoriatic Arthritis

Tofacitinib or Adalimumab vs Placebo for Patients With Psoriatic Arthritis

Tofacitinib may provide an alternate therapeutic mechanism of action for patients with psoriatic arthritis who have failed prior treatment with conventional synthetic disease-modifying antirheumatic drugs.

In-Depth Focus from ACR 2017: Spondyloarthritis Abatacept Improves Outcomes in Patients With Active Psoriatic Arthritis

Abatacept Improves Outcomes in Patients With Active Psoriatic Arthritis

Administration of abatacept may improve patient-reported outcomes in individuals with active psoriatic arthritis and elevated levels of C-reactive protein, irrespective of tumor necrosis factor inhibitor treatment history.

In-Depth Focus from ACR 2017: Spondyloarthritis Draft Psoriatic Arthritis Guideline Presented at ACR 2017

Draft Psoriatic Arthritis Guideline Presented at ACR 2017

The guideline includes recommendations for treating adult patients with active psoriatic arthritis.

In-Depth Focus from ACR 2017: Spondyloarthritis Secukinumab Effective for Inhibiting Radiographic Progression in PsA

Secukinumab Effective for Inhibiting Radiographic Progression in PsA

Regardless of dose, patients taking secukinumab were more likely to experience no radiographic progression compared with placebo.

Psoriatic Arthritis Rebound in Disease Activity in Patients With PsA After TNFi Discontinuation

Rebound in Disease Activity in Patients With PsA After TNFi Discontinuation

The risk for symptom flares is substantial after TNFi discontinuation in patients with psoriatic arthritis who had achieved remission/low disease activity.

Practice Management Online Consultation System Benefits Rheumatic Disease Management

Online Consultation System Benefits Rheumatic Disease Management

The SSDM series of applications is cost-effective for patients of rheumatologists.

In-Depth Focus from ACR 2017: Spondyloarthritis Tofacitinib Improves Patient-Reported Outcomes for Active Psoriatic Arthritis

Tofacitinib Improves Patient-Reported Outcomes for Active Psoriatic Arthritis

Results from phase 3 trials OPAL Broaden (NCT01877668) and OPAL Beyond (NCT01882439) presented at the American College of Rheumatology 2017 in San Diego, California.

In-Depth Focus from ACR 2017: Spondyloarthritis Therapeutic Goal Achievement Independent of Cardiovascular Risk in Psoriatic Arthritis

Therapeutic Goal Achievement Independent of Cardiovascular Risk in Psoriatic Arthritis

With the exception of sedentary lifestyle, cardiovascular risk factors were not found to impact the likelihood of achieving minimal disease activity among patients with psoriatic arthritis.

In-Depth Focus from ACR 2017: Spondyloarthritis Higher Prevalence of Depression, ADHD Observed Among Women With Psoriatic Arthritis

Higher Prevalence of Depression, ADHD Observed Among Women With Psoriatic Arthritis

Researchers observed a higher prevalence of psychiatric disorders among female patients with psoriatic arthritis.

Sign Up for Free e-newsletters